title: Recombinant transforming growth factor beta 1 and beta 2 protect mice from acutely lethal doses of 5-fluorouracil and doxorubicin.
abstract: Transforming growth factor beta 1 (TGF-beta 1) and TGF-beta 2 can reversibly inhibit the proliferation of hematopoietic progenitor cells in vivo, leading us to hypothesize that such quiescent progenitors might be more resistant to high doses of cell cycle active chemotherapeutic drugs, thereby allowing dose intensification of such agents. Initial studies showed that whereas administration of TGF-beta 1 or TGF-beta 2 did not prevent death in normal mice treated with high doses of 5-fluorouracil (5-FU), those mice that received TGF-beta 2 did exhibit the beginning of a hematologic recovery by day 11 after administration of 5-FU, and were preferentially rescued by a suboptimal number of transplanted bone marrow cells. Subsequently, it was found that the administration of TGF-beta 2 protected recovering progenitor cells from high concentrations of 5-FU in vitro. This protection coincided with the finding that significantly more progenitors for colony-forming unit-culture (CFU-c) and CFU-granulocyte, erythroid, megakaryocyte, macrophage (GEMM) were removed from S-phase by TGF-beta in mice undergoing hematopoietic recovery than in normal mice. Further studies showed that the administration of TGF-beta protected up to 90% of these mice undergoing hematologic recovery from a rechallenge in vivo with high dose 5-FU, while survival in mice not given TGF-beta was < 40%. Pretreatment of mice with TGF-beta 1 or TGF-beta 2 also protected 70-80% of mice from lethal doses of the noncycle active chemotherapeutic drug, doxorubicin hydrochloride (DXR). These results demonstrate that TGF-beta can protect mice from both the lethal hematopoietic toxicity of 5-FU, as well as the nonhematopoietic toxicity of DXR. This report thus shows that a negative regulator of hematopoiesis can be successfully used systemically to mediate chemoprotection in vivo.
authors.affiliation: Biological Carcinogenesis and Development Program, PRI/DynCorp, Frederick, Maryland.
authors.forename: K
authors.initials: K
authors.lastname: Grzegorzewski
authors.forename: F W
authors.initials: FW
authors.lastname: Ruscetti
authors.forename: N
authors.initials: N
authors.lastname: Usui
authors.forename: G
authors.initials: G
authors.lastname: Damia
authors.forename: D L
authors.initials: DL
authors.lastname: Longo
authors.forename: J A
authors.initials: JA
authors.lastname: Carlino
authors.forename: J R
authors.initials: JR
authors.lastname: Keller
authors.forename: R H
authors.initials: RH
authors.lastname: Wiltrout
mesh_terms: D000818:Animals; D001853:Bone Marrow / Q000187:drug effects; D016026:Bone Marrow Transplantation; D002455:Cell Division / Q000187:drug effects; D004317:Doxorubicin / Q000633:toxicity*; D005472:Fluorouracil / Q000633:toxicity*; D006412:Hematopoietic Stem Cells / Q000187:drug effects / Q000502:physiology; D051379:Mice; D008807:Mice, Inbred BALB C; D011994:Recombinant Proteins / Q000494:pharmacology; D016212:Transforming Growth Factor beta / Q000494:pharmacology*
chemical_list: D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; D004317:Doxorubicin; D005472:Fluorouracil